Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 2,10 M
EBIT 2016 -53,2 M
Net income 2016 -50,2 M
Debt 2016 -
Yield 2016 -
Sales 2017 0,50 M
EBIT 2017 -60,9 M
Net income 2017 -56,5 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 70,2x
Capi. / Sales 2017 295x
Capitalization 147 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on developing and commercializing products to treat treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
05/09 ANTHERA PHARMACEUTICALS : reports 1Q loss
05/09 Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quart..
04/30 ANTHERA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Change..
04/28 ANTHERA PHARMACEUTICALS : Greenphire Empowers Orphan Drug and Rare Disease Clini..
04/27 Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors
04/27 MEDICINES : Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors
04/22 ANTHERA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Termin..
03/10 ANTHERA PHARMACEUTICALS : Results of Operations and Financial Condition, Financi..
More news
Sector news : Bio Therapeutic Drugs
04:16pDJNant Health Seeks $82 Million in IPO
01:02p ALKERMES : to Present Data on ALKS 5461 at Upcoming American Society of Clinical..
05/23 AMGEN : Senior Leaders Advance Discussion on Cancer at 2016 World Medical Innova..
More sector news : Bio Therapeutic Drugs
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions